Tobramycin Inhalant Product — Competitive Intelligence Brief

Tobramycin Inhalant Product (Tobramycin Inhalant Product) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aminoglycoside antibiotic. Area: Infectious Disease / Pulmonology.

marketed Aminoglycoside antibiotic Bacterial 30S ribosomal subunit Infectious Disease / Pulmonology Small molecule

Target snapshot

Tobramycin Inhalant Product (Tobramycin Inhalant Product) — Shanghai Pulmonary Hospital, Shanghai, China. Tobramycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, leading to bactericidal activity against aerobic gram-negative and some gram-positive bacteria.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tobramycin Inhalant Product TARGET	Tobramycin Inhalant Product	Shanghai Pulmonary Hospital, Shanghai, China	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
Cefazolin + Gentamicin	Cefazolin + Gentamicin	Mercy Health Ohio	marketed	Beta-lactam antibiotic + aminoglycoside antibiotic combination	Bacterial penicillin-binding proteins (cefazolin); bacterial 30S ribosomal subunit (gentamicin)
Tobramycin once a day	Tobramycin once a day	Oslo University Hospital	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
Minocycline HCl	Minocycline HCl	OraPharma	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Gentamicin - three days	Gentamicin - three days	Murdoch Childrens Research Institute	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
Usual doses of tigecycline	Usual doses of tigecycline	Air Force Specialized Hospital, Cairo, Egypt	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Amikacin Injection	Amikacin Injection	Murdoch Childrens Research Institute	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aminoglycoside antibiotic class)

1. U.S. Army Medical Research and Development Command · 2 drugs in this class
2. Hospital General Universitario Elche · 2 drugs in this class
3. Murdoch Childrens Research Institute · 2 drugs in this class
4. Public Health Service of Amsterdam · 1 drug in this class
5. Seattle Children's Hospital · 1 drug in this class
6. Shanghai Pulmonary Hospital, Shanghai, China · 1 drug in this class
7. Shanghai Zhongshan Hospital · 1 drug in this class
8. South Australian Health and Medical Research Institute · 1 drug in this class
9. The University of Queensland · 1 drug in this class
10. University of Leipzig · 1 drug in this class